tetano
Editor, Senior Moderator
Clin Infect Dis
. 2024 Sep 26:ciae465.
doi: 10.1093/cid/ciae465. Online ahead of print. Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial
Youyi Fong[SUP] 1 2 3 [/SUP], Lauren Dang[SUP] 4 [/SUP], Bo Zhang[SUP] 1 [/SUP], Jonathan Fintzi[SUP] 4 [/SUP], Shiyu Chen[SUP] 1 [/SUP], Jing Wang[SUP] 5 [/SUP], Nadine G Rouphael[SUP] 6 [/SUP], Angela R Branche[SUP] 7 [/SUP], David J Diemert[SUP] 8 [/SUP], Ann R Falsey[SUP] 7 [/SUP], Cecilia Losada[SUP] 6 [/SUP], Lindsey R Baden[SUP] 9 [/SUP], Sharon E Frey[SUP] 10 [/SUP], Jennifer A Whitaker[SUP] 11 [/SUP], Susan J Little[SUP] 12 [/SUP], Satoshi Kamidani[SUP] 13 14 [/SUP], Emmanuel B Walter[SUP] 15 [/SUP], Richard M Novak[SUP] 16 [/SUP], Richard Rupp[SUP] 17 [/SUP], Lisa A Jackson[SUP] 18 [/SUP], Chenchen Yu[SUP] 1 [/SUP], Craig A Magaret[SUP] 1 [/SUP], Cindy Molitor[SUP] 1 [/SUP], Bhavesh Borate[SUP] 1 [/SUP], Tara M Babu[SUP] 19 [/SUP], Angelica C Kottkamp[SUP] 20 [/SUP], Anne F Luetkemeyer[SUP] 21 [/SUP], Lilly C Immergluck[SUP] 22 [/SUP], Rachel M Presti[SUP] 23 [/SUP], Martín Bäcker[SUP] 24 [/SUP], Patricia L Winokur[SUP] 25 [/SUP], Siham M Mahgoub[SUP] 26 [/SUP], Paul A Goepfert[SUP] 27 [/SUP], Dahlene N Fusco[SUP] 28 [/SUP], Robert L Atmar[SUP] 11 [/SUP], Christine M Posavad[SUP] 29 30 [/SUP], Jinjian Mu[SUP] 31 [/SUP], Mat Makowski[SUP] 31 [/SUP], Mamodikoe K Makhene[SUP] 32 [/SUP], Seema U Nayak[SUP] 32 [/SUP], Paul C Roberts[SUP] 32 [/SUP], Dean Follmann[SUP] 4 [/SUP], Peter B Gilbert[SUP] 1 2 3 [/SUP]; Coronavirus Variant Immunologic Landscape Trial (COVAIL) Study Team
Collaborators, Affiliations
For COVAIL recipients of a COVID-19 Sanofi booster vaccine, neutralizing antibody titers were assessed as a correlate of risk (CoR) of COVID-19. Peak and exposure-proximal titers were inverse CoRs with covariate-adjusted hazard ratios (95% confidence intervals) 0.30 (0.11, 0.78) and 0.25 (0.07, 0.85) per 10-fold increase in weighted average titer.
Keywords: COVID-19 booster; Omicron; correlate of risk; exposure-proximal titer; variant vaccine booster.
. 2024 Sep 26:ciae465.
doi: 10.1093/cid/ciae465. Online ahead of print. Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial
Youyi Fong[SUP] 1 2 3 [/SUP], Lauren Dang[SUP] 4 [/SUP], Bo Zhang[SUP] 1 [/SUP], Jonathan Fintzi[SUP] 4 [/SUP], Shiyu Chen[SUP] 1 [/SUP], Jing Wang[SUP] 5 [/SUP], Nadine G Rouphael[SUP] 6 [/SUP], Angela R Branche[SUP] 7 [/SUP], David J Diemert[SUP] 8 [/SUP], Ann R Falsey[SUP] 7 [/SUP], Cecilia Losada[SUP] 6 [/SUP], Lindsey R Baden[SUP] 9 [/SUP], Sharon E Frey[SUP] 10 [/SUP], Jennifer A Whitaker[SUP] 11 [/SUP], Susan J Little[SUP] 12 [/SUP], Satoshi Kamidani[SUP] 13 14 [/SUP], Emmanuel B Walter[SUP] 15 [/SUP], Richard M Novak[SUP] 16 [/SUP], Richard Rupp[SUP] 17 [/SUP], Lisa A Jackson[SUP] 18 [/SUP], Chenchen Yu[SUP] 1 [/SUP], Craig A Magaret[SUP] 1 [/SUP], Cindy Molitor[SUP] 1 [/SUP], Bhavesh Borate[SUP] 1 [/SUP], Tara M Babu[SUP] 19 [/SUP], Angelica C Kottkamp[SUP] 20 [/SUP], Anne F Luetkemeyer[SUP] 21 [/SUP], Lilly C Immergluck[SUP] 22 [/SUP], Rachel M Presti[SUP] 23 [/SUP], Martín Bäcker[SUP] 24 [/SUP], Patricia L Winokur[SUP] 25 [/SUP], Siham M Mahgoub[SUP] 26 [/SUP], Paul A Goepfert[SUP] 27 [/SUP], Dahlene N Fusco[SUP] 28 [/SUP], Robert L Atmar[SUP] 11 [/SUP], Christine M Posavad[SUP] 29 30 [/SUP], Jinjian Mu[SUP] 31 [/SUP], Mat Makowski[SUP] 31 [/SUP], Mamodikoe K Makhene[SUP] 32 [/SUP], Seema U Nayak[SUP] 32 [/SUP], Paul C Roberts[SUP] 32 [/SUP], Dean Follmann[SUP] 4 [/SUP], Peter B Gilbert[SUP] 1 2 3 [/SUP]; Coronavirus Variant Immunologic Landscape Trial (COVAIL) Study Team
Collaborators, Affiliations
- PMID: 39325506
- DOI: 10.1093/cid/ciae465
For COVAIL recipients of a COVID-19 Sanofi booster vaccine, neutralizing antibody titers were assessed as a correlate of risk (CoR) of COVID-19. Peak and exposure-proximal titers were inverse CoRs with covariate-adjusted hazard ratios (95% confidence intervals) 0.30 (0.11, 0.78) and 0.25 (0.07, 0.85) per 10-fold increase in weighted average titer.
Keywords: COVID-19 booster; Omicron; correlate of risk; exposure-proximal titer; variant vaccine booster.